94-17809. Implantation or Injectable Dosage Form New Animal Drugs; Melatonin Implant  

  • [Federal Register Volume 59, Number 140 (Friday, July 22, 1994)]
    [Unknown Section]
    [Page 0]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 94-17809]
    
    
    [[Page Unknown]]
    
    [Federal Register: July 22, 1994]
    
    
    -----------------------------------------------------------------------
    
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    21 CFR Part 522
    
     
    
    Implantation or Injectable Dosage Form New Animal Drugs; 
    Melatonin Implant
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
    drug regulations to reflect approval of a new animal drug application 
    (NADA) filed by Wildlife Laboratories, Inc. The NADA provides for the 
    subcutaneous use of melatonin implant in healthy male and female kit 
    and adult female mink to accelerate the fur priming cycle.
    
    EFFECTIVE DATE: July 22, 1994.
    
    FOR FURTHER INFORMATION CONTACT: Marcia K. Larkins, Center for 
    Veterinary Medicine (HFV-112), Food and Drug Administration, 7500 
    Standish Pl., Rockville, MD 20855, 301-594-0614.
    
    SUPPLEMENTARY INFORMATION: Wildlife Laboratories, Inc., 1401 Duff Dr., 
    suite 600, Fort Collins, CO 80524, filed NADA 140-846 which provides 
    for the subcutaneous use of melatonin implant in healthy male and 
    female kit and adult female mink (Mustela vison) to accelerate the fur 
    priming cycle. The drug product is an implant consisting of a silicone 
    rubber elastomer that contains 2.7 milligrams of homogeneously 
    dispersed melatonin. The NADA is approved as of June 21, 1994, and the 
    regulations are amended in part 522 (21 CFR part 522) by adding new 
    Sec. 522.1350 to reflect the approval. The basis for approval is 
    discussed in the freedom of information summary.
        In accordance with the freedom of information provisions of part 20 
    (21 CFR part 20) and Sec. 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a 
    summary of safety and effectiveness data and information submitted to 
    support approval of this application may be seen in the Dockets 
    Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 
    12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., 
    Monday through Friday.
        Under section 512(c)(2)(F)(i) of the Federal Food, Drug, and 
    Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(i)), this approval qualifies for 
    5 years of marketing exclusivity beginning June 21, 1994, because no 
    active ingredient (including any ester or salt of the active 
    ingredient) has been approved in any other application.
        The agency has carefully considered the potential environmental 
    effects of this action. FDA has concluded that the action will not have 
    a significant impact on the human environment, and that an 
    environmental impact statement is not required. The agency's finding of 
    no significant impact and the evidence supporting that finding, 
    contained in an environmental assessment, may be seen in the Dockets 
    Management Branch (address above) between 9 a.m. and 4 p.m., Monday 
    through Friday.
    
    List of Subjects in 21 CFR Part 522
    
        Animal drugs.
        Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
    authority delegated to the Commissioner of Food and Drugs and 
    redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is 
    amended as follows:
    
    PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
    
        1. The authority citation for 21 CFR part 522 continues to read as 
    follows:
    
        Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act 
    (21 U.S.C. 360b).
    
        2. New Sec. 522.1350 is added to read as follows:
    
    
    Sec. 522.1350  Melatonin implant.
    
        (a) Specifications. The drug is a silicone rubber elastomer implant 
    containing 2.7 milligrams of melatonin.
        (b) Sponsor. See No. 053923 in Sec. 510.600(c) of this chapter.
        (c) Conditions of use--(1) Amount. One implant per mink.
        (2) Indications for use. For use in healthy male and female kit and 
    adult female mink (Mustela vison) to accelerate the fur priming cycle.
        (3) Limitations. For subcutaneous implantation in mink only. Do not 
    implant potential breeding stock. Do not use in food-producing animals.
    
        Dated: July 15, 1994.
     Stephen F. Sundlof,
     Director, Center for Veterinary Medicine.
    [FR Doc. 94-17809 Filed 7-21-94; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
07/22/1994
Department:
Health and Human Services Department
Entry Type:
Uncategorized Document
Action:
Final rule.
Document Number:
94-17809
Dates:
July 22, 1994.
Pages:
0-0 (1 pages)
Docket Numbers:
Federal Register: July 22, 1994
CFR: (1)
21 CFR 522.1350